美国Watson Pharmaceuticals, Inc. www.watson.com
2006年 制药厂商Watson Pharmaceuticals决定以大约19亿美元收购Andrx，以壮大其非专利药(generic drug)业务，在迅速整合的产业中与较大的对手并驾齐驱。

　　Watson表示，上述并购将使其成为美国第三大非专利药厂商。它将以每股25美元的价格收购Andrx，较过去30天Andrx的平均股价溢价32%。预计上述交易将增加其2007年获利。

　　合并后的公司将拥有超过60项非专利药的申请。Watson表示，预计今年将推出8种或更多新药。
2013年Watson Pharmaceuticals更名为Actavis 

   


Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets and distributes brand and generic pharmaceutical products. With one of the broadest product offerings in the U.S. generics industry and a track record of service excellence, Watson has earned a solid reputation as a reliable and low-cost provider of quality pharmaceutical products.